F. J. Barrios

发表

Abstract PD1-08: Oral paclitaxel and encequidar (oPac+E) versus IV paclitaxel (IVPac) in the treatment of metastatic breast cancer (mBC) patients (study KX-ORAX-001): Progression free survival (PFS) and overall survival (OS) updates

H. Rugo, Hui Wang, D. Cutler, 2021 .

Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer

H. Rugo, L. Fein, R. Kowalyszyn, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.